

AMENDMENTS TO THE CLAIMS

Please replace all previous listings, and versions, of the claims with the following claims, where text to be added is indicated by underlining and text to be deleted is indicated by strikethrough.

1-38. (Cancelled)

39. (Currently amended) A kit comprising:

a multimeric compound homo-multimeric anti-P-Selectin Glycoprotein Ligand-1 (PSGL-1) antibody selected based on its ability both to bind specifically to PSGL-1 on the surface of an activated T cell and to induce apoptosis of the activated T cell that binds to at least two P-Selectin Glycoprotein-1 (PSGL-1) proteins on the surface of a T cell, wherein the multimeric compound homo-multimeric anti-PSGL-1 antibody comprises two polypeptide chains, each of the polypeptide chains comprising (i) a binding domain that binds to PSGL-1, and (ii) a heterologous amino acid sequence, wherein the polypeptide chains are linked via the heterologous amino acid sequence to form the multimeric compound homo-multimeric anti-PSGL-1 antibody, wherein the binding of the multimeric compound to the at least two PSGL-1 proteins on the surface of the T cell induces a signal transduction pathway that results in death of the T cell; and

instructions for use of the multimeric compound homo-multimeric anti-PSGL-1 antibody to treat inflammation, autoimmunity, transplant rejection, an allergic condition, or a T cell cancer;

wherein the multimeric compound is a homo-multimeric anti-PSGL-1 antibody.

40. (Previously Presented) The kit according to claim 39, wherein the homo-multimeric anti-PSGL-1 antibody is a chimeric anti-PSGL-1 antibody.

41. (Previously Presented) The kit according to claim 39, wherein the homo-multimeric anti-PSGL-1 antibody is a humanized anti-PSGL-1 antibody.